ABIQUIFI In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the inequality decreases, so have barriers to purchasing medicines. Greater employment has clearly been an important factor, which also contributes via…
Abbott Hungary You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can you provide our readers with a better idea on the business environment as you took over the operations here? After…
Lundbeck Philippines You have been involved with Lundbeck since the beginning of its operations in the Philippines. How has the company evolved since you joined seven years ago to be where it stands now? I was contacted by the Lundbeck Regional Vice President in late 2002 and asked to come for an…
Bogin Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics industry, I would like to begin please with a brief history of Bogin. What was the market landscape in the…
Panacea Biotec The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian biotech sector stand today within an international context? Indian biotech companies, in particular in the vaccines industry, would be among…
Bausch and Lomb Czech Republic Mr. Bruzl, we often interview pharmaceutical managers that studied medicine, pharmaceutical science, or business—we do not interview many managers that have a background in law. How did you find yourself working for this industry? Do you find that it has been a good fit for you? When I was studying…
Crown Bioscience Hu Jintao recently announced his ambitions for China to be “an innovative country” by 2020? Could you speak to the likelihood of achieving this in terms of biotechnology as you see it? In the biotech area, China has come a long way. I got my college undergraduate degree in China…
India Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian pharma market, and strategy moving forward. Last year Micro Labs moved up in the rankings. How satisfied are you with the company’s performance in 2010? The company performed satisfactorily last year, showing good…
Arch Pharmalabs Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD company with 11 manufacturing plants. What triggered the acquisition of the Hyderabad plant, and what have been the main milestones…
Dr Reddy's Laboratories Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain the situation there and what measures did you take to turn the situation around? Germany, and in particular the Betapharm…
Janssen Czech Republic & Slovakia Infirmary and ultimately leading to a position heading the Czech Republic and Slovakian organization for Janssen. Can you begin by introducing yourself to our readers and giving them an overview of your professional trajectory? Indeed, I started off as a nurse in the North of Scotland where I specialized in…
See our Cookie Privacy Policy Here
